298 related articles for article (PubMed ID: 15972445)
1. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Chen R; Keating MJ; Gandhi V; Plunkett W
Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
3. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
4. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
Kitada S; Zapata JM; Andreeff M; Reed JC
Blood; 2000 Jul; 96(2):393-7. PubMed ID: 10887097
[TBL] [Abstract][Full Text] [Related]
8. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
9. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.
Venkataraman G; Maududi T; Ozpuyan F; Bahar HI; Izban KF; Qin JZ; Alkan S
Leuk Res; 2006 Nov; 30(11):1377-84. PubMed ID: 16624404
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy.
Lee YK; Isham CR; Kaufman SH; Bible KC
Mol Cancer Ther; 2006 Jan; 5(1):138-48. PubMed ID: 16432172
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
13. The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract.
Zaher M; Mirshahi M; Nuraliev Y; Sharofova M; Bombarda I; Marie JP; Billard C
Int J Oncol; 2011 Oct; 39(4):965-72. PubMed ID: 21750864
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia.
Billard C; Kern C; Tang R; Ajchenbaum-Cymbalista F; Kolb JP
Leukemia; 2003 Dec; 17(12):2435-43. PubMed ID: 14523476
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine.
Balakrishnan K; Wierda WG; Keating MJ; Gandhi V
Clin Cancer Res; 2005 Sep; 11(18):6745-52. PubMed ID: 16166456
[TBL] [Abstract][Full Text] [Related]
17. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
Bonvini P; Zorzi E; Mussolin L; Monaco G; Pigazzi M; Basso G; Rosolen A
Haematologica; 2009 Jul; 94(7):944-55. PubMed ID: 19535344
[TBL] [Abstract][Full Text] [Related]
18. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Pei XY; Dai Y; Grant S
Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
Chen R; Guo L; Chen Y; Jiang Y; Wierda WG; Plunkett W
Blood; 2011 Jan; 117(1):156-64. PubMed ID: 20971952
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.
Hussain SR; Lucas DM; Johnson AJ; Lin TS; Bakaletz AP; Dang VX; Viatchenko-Karpinski S; Ruppert AS; Byrd JC; Kuppusamy P; Crouser ED; Grever MR
Blood; 2008 Mar; 111(6):3190-9. PubMed ID: 18192508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
